OsteoRemedies® Obtains Expanded Indications for SPECTRUM® Dual Antibiotic Bone Cement
Retrieved on:
Tuesday, April 23, 2024
MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.
Key Points:
- MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.
- Initially launched in 2018, SPECTRUM® GV Bone Cement is the first commercially available dual antibiotic bone cement on the US market.
- Containing both vancomycin and gentamicin, SPECTRUM® GV Bone Cement prevents bacterial adhesion of susceptible organisms, intermediate-resistant, and methicillin-resistant staphylococcal infections.
- From a mechanical performance perspective, testing of SPECTRUM® GV Bone Cement has been compared to commercially available single antibiotic bone cements and found to have substantially equivalent mechanical integrity.